Enfortumab vedotin

Enfortumab vedotin-ejfv (PADCEV®) is a first-in-class antibody–drug conjugate (ADC) directed against Nectin-4, a protein located on the surface of cells that is highly expressed in bladder cancer.^1,2

Nonclinical data suggest the anticancer activity of enfortumab vedotin is due to binding to Nectin-4–expressing cells, followed by the internalization and release of the anti-tumor agent monomethyl auristatin E (MMAE) into the cell. This is believed to prevent cell reproduction (cell cycle arrest) and to cause programmed cell death (apoptosis).¹

Enfortumab vedotin is being developed in collaboration with Astellas.

Enfortumab vedotin is an investigational agent in this setting. Its safety and efficacy have not yet been established.